BridgeMD
Compares treatment options for İron Deficiency Anemia
Official title Liposomal vs Conventional Oral Iron After Sleeve Gastrectomy
ClinicalTrials.gov ID: NCT07366502
What this study is testing
What is Liposomal Iron?
Liposomal Iron is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for i̇ron deficiency anemia.
Also referred to as nano encapsule bioferrP.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Low-dose liposomal iron (17-34 mg elemental/day) was compared with standard conventional oral iron (100-200mg elemental/day) in the treatment of iron deficiency anemia following sleeve gastrectomy. Liposomal iron provided superior hematological improvement and gastrointestinal tolerance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Age between 18 and 65 years
- History of laparoscopic sleeve gastrectomy performed at least 6 months prior to enrollment
- Diagnosis of iron deficiency anemia, defined as:
- Hemoglobin \<12 g/dL in women or \<13 g/dL in men, and
- Serum ferritin \<30 ng/mL or transferrin saturation (TSAT) \<20%
You likely can't join if
- Active gastrointestinal disease (e.g., inflammatory bowel disease, peptic ulcer disease, or gastrointestinal bleeding)
- Chronic kidney disease with estimated GFR \<30 mL/min/1.73 m²
- Use of oral or parenteral iron, vitamin B12, or folate supplementation within the previous 3 months
- Iron overload or hemochromatosis (serum ferritin \>300 ng/mL)
- Known allergy or intolerance to iron preparations
- Active malignancy
See the full eligibility criteria
- Age between 18 and 65 years
- History of laparoscopic sleeve gastrectomy performed at least 6 months prior to enrollment
- Diagnosis of iron deficiency anemia, defined as:
- Hemoglobin \<12 g/dL in women or \<13 g/dL in men, and
- Serum ferritin \<30 ng/mL or transferrin saturation (TSAT) \<20%
- Mild to moderate anemia (hemoglobin ≥9 g/dL)
- Ability to take and swallow oral medications
- Willingness to participate and provide written informed consent
- Active gastrointestinal disease (e.g., inflammatory bowel disease, peptic ulcer disease, or gastrointestinal bleeding)
- Chronic kidney disease with estimated GFR \<30 mL/min/1.73 m²
- Use of oral or parenteral iron, vitamin B12, or folate supplementation within the previous 3 months
- Iron overload or hemochromatosis (serum ferritin \>300 ng/mL)
- Known allergy or intolerance to iron preparations
- Active malignancy
- Pregnancy or breastfeeding
- Known hemoglobinopathies (e.g., thalassemia, sickle cell disease)
- Blood transfusion within the previous 1 month
- Cognitive or psychiatric disorder interfering with study participation or protocol adherence
The study team makes the final eligibility decision.
Where it's taking place
- Istanbul, kadıköy, Turkey (Türkiye)
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Istanbul, kadıköy, Turkey (Türkiye). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.